This Danaos Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Tiger Global Management Increases Stake In Coupang Inc By 5% To 36,467,972 Shares.

Jim Cramer Says Buy Carpenter Technology, Calls This IT Services Stock a 'Value Trap'

Cramer recommends buying Carpenter Technology (NYSE: CRS) and calls DXC Technology (NYSE: DXC) a value trap. Senseonics Holdings (NASDAQ: SENS) posts upbeat sales and Ubiquiti (NYSE: UI) reports worse-than-expected results. Hess Midstream (NYSE: HESM) is a winner while Zeta Global (NYSE: ZETA) announces a new CMO. UL Solutions (NYSE: ULS) is a potential buy and Coupang (NYSE: CPNG) is not recommended, but MercadoLibre (NASDAQ: MELI) and Amazon (NASDAQ: AMZN) are worth considering.

Amazon.com vs. Coupang: Which Consumer Stock Is a Better Buy in 2026?

The article compares Amazon and Coupang as e-commerce investment options for 2026. Amazon demonstrates superior financial health with a 10.8% net margin, $3.0T market cap, and diversified revenue streams including AWS and advertising. Coupang, despite 14.1% revenue growth, struggles with a 0.6% net margin, recent data breach fallout, regulatory fines, and currency headwinds. The author recommends Amazon for long-term investors due to its scale, profitability, momentum, and lower risk profile compared to Coupang's multiple near-term challenges.

Paycom Software To Rally Around 32%? Here Are 10 Top Analyst Forecasts For Thursday

Analysts changed outlook on top names: JP Morgan cut price target for Insulet, HC Wainwright slashed EyePoint's target, Goldman cut Sunrun's, B of A lowered Coupang's, BTIG cut Klaviyo's, Jefferies raised J&J Snack Foods', Raymond James raised Select Water Solutions', and Freedom Broker raised Danaos'.

Animal Testing and Non-Animal Alternative Testing Market Outlook 2025-2035 - Featuring Profiles of Charles River Laboratories, Labcorp, and Eurofins Scientific

The global animal testing and non-animal alternative testing market reached $15.19 billion in 2025 and is projected to grow to $23.01 billion by 2035 at a CAGR of 4-4.5%. While animal testing dominated with 80.1% market share in 2025, non-animal alternative testing is expected to grow faster at 6.3% CAGR through 2030, driven by advances in organ-on-chip, organoids, AI biosimulation, and genomics. The pharmaceutical industry led end-user applications with 50.1% market share, while North America was the largest regional market at 38.6% of global revenue.

Large Molecule Bioanalytical Testing Services Global Market Report 2026-2035 | Identify High-Growth Opportunities and Develop Informed Commercial Strategies

The global large molecule bioanalytical testing services market is projected to grow from USD 3.11 billion in 2026 to USD 5.88 billion by 2035, with a CAGR of 7.3%. Growth is driven by increasing biologics pipelines, demand for personalized therapies, and outsourcing to CROs and CDMOs. Pharmacokinetics testing dominates at 45% of market revenue, while bioequivalence testing is expected to grow fastest. North America leads with 50% of global revenue, while Asia-Pacific is the fastest-growing region at 8.6% CAGR.